Moderna Submits JN.1 COVID Vaccine Application Following FDA Advice

Moderna has submitted an application to FDA for a 2024-2025 formula of its mRNA COVID-19 vaccine targeting the JN.1 strain of the virus, the company announced Friday (June 7), after receiving guidance from the agency advising that strain should be used. FDA’s top biological official Peter Marks sparred with agency advisors over strain selection this week, with Marks advocating for selecting the KP.2 strain, which only mRNA vaccine makers can produce in time for the fall respiratory virus season, while...